Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379:111-121.
Published: 17th September 2018
Authors: Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al.
This trial included over then thousand women with ER positive, HER-2 negative breast cancer. Endocrine therapy alone was not inferior: hazard ratio for disease recurrence, second primary or death 1.09, 95 per cent confidence interval 0.94 to 1.24. Chemotherapy may benefit women aged 50 and under.Pubmed Link
You may also be interested in
Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.
Authors: Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L et al.
Six months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019; 393: 2591-2598.
Authors: Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T et al.
Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. JAMA Oncol 2019; 5:e190339.
Authors: Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC et al.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-1452.
Authors: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-628.
Authors: Von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al.
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J Clin Oncol 2018; 36: 3126-3133.
Authors: Bardia A, Parton M, Kummel S, Estevez LG, Huang C-S, Cortes J et al.
Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node–positive and high-risk lymph node–negative breast cancer (E5103). J Clin Oncol 2018; 36: 2621-2629.
Authors: Miller KD, O’Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA et al.
Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor–treated patients: CCTG MA.27. J Natl Cancer Inst 2018; 110: 1003–1008.
Authors: Strasser-Weippl K, Higgins MJ, Chapman J-AW, Ingle JN, Sledge GW, Budd GT et al.
Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122-137.
Authors: Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I et al.
Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst 2018; 110: 40-48.
Authors: Blok EJ, Kroep JR, Kranenbarg EM-K, Duijm-de Carpentier M, Putter H, van den Bosch J et al.
De-escalation strategies in human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (BC): final analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor–positive phase II randomized trial—efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol 2017; 35: 3046-3054.
Authors: Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S et al.
Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 2017; 35: 2639-2646.
Authors: Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen M-B, Knoop AS, Højris I et al.